Abstracts Archive - Page 2124 of 2607 - ACR Meeting Abstracts

Abstract Number: 1661 • 2014 ACR/ARHP Annual Meeting
Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares?
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is the major cause of morbidity and mortality in patients with systemic lupus erythematosus. The role of repeat kidney biopsies (RB)…
Abstract Number: 1660 • 2014 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis of Cyclophosphamide and Mycophenolate Mofetil in Lupus Nephritis
Jasvinder A. Singh¹, Ahmed Kotb², Alomgir Hossain² and George A. Wells³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada
Background/Purpose Patients consider common side effects of medications prominently in treatment decision-making. To our knowledge, with the exception of a Cochrane review that analyzed data…
Abstract Number: 1659 • 2014 ACR/ARHP Annual Meeting
The Clinical Relevance of a Repeat Biopsy in Lupus Nephritis (LN) Flares
Milagros Ricse¹, Javier Narváez², Gloria Albert¹, Paula Estrada¹, Sergi Heredia¹, Andrea Zacarias¹, Helena Borrell¹, Eulalia Armengol¹, Xavier Fulladosa³, Joan Torras³, Olga Capdevila⁴, Francesca Mitjavila⁴ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Renal biopsy is the gold standard for assessing renal activity and hence guiding treatment. Whether a repeat renal biopsy is helpful during flares of…
Abstract Number: 1657 • 2014 ACR/ARHP Annual Meeting
Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?
Eulalia Armengol¹, Javier Narváez², Helena Borrell¹, Sergi Heredia¹, Milagros Ricse¹, Eva Benavent³, Alex Roset³, Carmen Gomez Vaquero¹, Joan Torras⁴, Francesca Mitjavila³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that usually affects young people. Several reviews have shown that age may have an effect on…
Abstract Number: 1636 • 2014 ACR/ARHP Annual Meeting
Disease Phenotype Is Associated with TH1, TH2 and TH17 Cytokines in Childhood-Onset Systemic Lupus Erythematosus
Karina Oliveira Peliçari¹, Mariana Postal², Renata Brabosa³, Nailu A. Sinicato², Fernando Augusto Peres², Roberto Marini⁴ and Simone Appenzeller⁵, ¹State University of Campinas, Campinas, Brazil, ²Medicine, State University of Campinas, Campinas, Brazil, ³Medicine, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, ⁴Departament of Pediatrics, State University of Campinas, Campinas, Brazil, ⁵Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose Childhood-onset Systemic lupus erythematosus (cLES) is an autoimmune disease characterized by periods of activity and remission. There is a wide spectrum of manifestations, such…
Abstract Number: 1635 • 2014 ACR/ARHP Annual Meeting
Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function
Ashira Blazer¹, H. Michael Belmont², Robert Clancy³, Peter M. Izmirly⁴ and Jill P. Buyon⁵, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, NYU Medical Center, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose The apolipoprotein1 (APOL1) gene encodes a 3 domain protein found both in serum and intracellularly in endothelial cells among other cell types. Variant APOL1…
Abstract Number: 1634 • 2014 ACR/ARHP Annual Meeting
Thrombophilia Associated with DFS70 Antibodies
Julien Marlet¹, Jean- Luc Charuel¹, Isabelle Martin-Toutain², Pascale Ghillani-Dalbin¹, Zahir Amoura³, Annick Ankri⁴ and Makoto Miyara^1,5, ¹Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²Department of Hematology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁴Groupe Hospitalier Pitié Salpétrière, service d'hématologie biologique, Paris, France, ⁵Internal medicine 2, French national reference center for lupus and antiphospholipid syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
Background/Purpose The search for antinuclear antibodies (ANA) by indirect immunofluorescence (IIF) on Hep-2 cells is routinely performed as the first step for the biological diagnosis…
Abstract Number: 1633 • 2014 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Associated with Disease Activity, but Not with Atherosclerosis in SLE Patients
Susan Kay¹, Niels Heegaard² and Anne Voss³, ¹Rheumatolog, Rheumatology, Odense, Denmark, ²Cinical Biochemistry and Pharmacology, Cinical Biochemistry and Pharmacology, Odense, Denmark, ³Reumatology, Reumatology, Odense, Denmark
Background/Purpose . Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD), which may be due to an increased prevalence of atherosclerosis.…
Abstract Number: 1632 • 2014 ACR/ARHP Annual Meeting
Is Liopxin A4 a Biomarker for Systemic Lupus Erythematosus?
Manal Sedky Abdou¹, Dina Effat², Lamiaa Mansour³, Mona mohsen Abdul Salam³ and Noha abd El Baky⁴, ¹rheumatology and rehabilitation kasr el aini hospital, faculty of medicin, cairo university, cairo, Egypt, ²rheumatology and rehabilitation, faculty of medicin, cairo university, giza, Egypt, ³clinical and chemical pathology, faculty of medicin, cairo university, cairo, Egypt, ⁴rheumatology and rehabilitation, faculty of medicin, cairo university, cairo, Egypt
Background/Purpose : Systemic lupus erythematosus (SLE) is characterized by autoantibody production and immune complex deposition which trigger both a local and systemic inflammatory response. The…
Abstract Number: 1631 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Richard Furie¹, Jill P. Buyon², R. Ramsey-Goldman³, Chaim Putterman⁴, Kenneth Kalunian⁵, Tyler O'Malley⁶, John Conklin⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: To assess the association between cell bound complement activation products (CBCAPS) and measures of disease activity and quality of life in systemic lupus erythematosus…
Abstract Number: 1630 • 2014 ACR/ARHP Annual Meeting
A Novel NMR Biomarker of Inflammation (GlycA) Is Elevated in Systemic Lupus Erythematosus
Cecilia P. Chung¹, Michelle J. Ormseth^2,3, Annette M. Oeser³, Joseph F. Solus^3,4, Margery A. Connelly⁵, James D. Otvos⁶ and C. Michael Stein^3,7, ¹Medicine, Vanderbilt University, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴Medicine, Vanderbilt Medical Center, Nashville, TN, ⁵LipoScience, Inc., Raleigh, NC, ⁶LipoScience Inc., Raleigh, NC, ⁷Div of Clinical Pharmacology, Vanderbilt Univ School of Med, Nashville, TN
Background/Purpose: Nuclear magnetic resonance (NMR) spectra from samples analyzed for lipoproteins also contain a peak (termed GlycA) resulting from glycosylated proteins. GlycA is not only…
Abstract Number: 1629 • 2014 ACR/ARHP Annual Meeting
Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus
Johannes Schulte-Pelkum¹, Diana Carmona-Fernandes², Maria Jose Santos², Roger Albesa¹ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Background/Purpose Anti-dsDNA antibodies (aab) are known as important serological marker to aid in the diagnosis of systemic lupus erythematosus (SLE) and are part of the…
Abstract Number: 1628 • 2014 ACR/ARHP Annual Meeting
Upregulation of Myxovirus Resistance Protein 1 in Patients with Neuropsychiatric Systemic Lupus Erythematosus
Yuka Shimizu, Shinsuke Yasuda, Takashi Kurita, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Toshiyuki Watanabe, Michihito Kono, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Nervous system disease is one of the most common manifestations in patients with systemic lupus erythematosus (SLE) that significantly affects morbidity and mortality. Due…
Abstract Number: 1627 • 2014 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score (GAPSS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies
Savino Sciascia¹, Giovanni Sanna², Veronica Murru³, Dario Roccatello⁴, Munther A. Khamashta⁵ and Maria Laura Bertolaccini³, ¹12 Kennington Ave, Rayne Institute, St. Thomas Hospital, London, United Kingdom, ²Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁴CORSO RAFFAELLO 30, UNIVERSITY OF TURIN (ITALY), TURIN, Italy, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Arterial event are frequent in the antiphospholipid syndrome (APS) and stroke is a major clinical manifestation of syndrome. Recently, we conducted a study in…
Abstract Number: 1626 • 2014 ACR/ARHP Annual Meeting
Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE
Fleur Schaper¹, Gerda Horst¹, Daan van Beijeren Bergen en Henegouwen¹, Johan Bijzet¹, Karina de Leeuw¹, Alja Stel¹, Pieter C Limburg², Peter Heeringa³ and Johanna Westra¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: High mobility group box 1 (HMGB1) is a damage-associated molecular pattern and can be divided in three separate domains: the A Box, B Box…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].